North China Pharmaceutical Group Co., Ltd.

North China Pharmaceutical Group Co., Ltd. (referred to as: China Pharmaceutical group) is one of the chemical pharmaceutical companies in China, located in Shijiazhuang City, capital of Hebei province. The predecessor of North China Pharmaceutical Factory is China's "15" plan period of the key construction projects, began to build in June 1953, built into production in June 1958, creating a large-scale production of antibiotics in China's history, in order to change the situation of China's shortage of medicine has made an important contribution. 1992 reorganization set up North China Pharmaceutical Co., Ltd., 1994 listed in Shanghai. January 1996, North China Pharmaceutical Factory formally restructured into a wholly state-owned company-a north China pharmaceutical Group Limited liability company. June 2009, approved by the Hebei provincial government, Jizhong Energy group has implemented a reorganization of China Pharmaceutical group.
Over the years, China Pharmaceutical Group Continuous innovation, sound management, gradually grow, business scope continues to expand, the development of performance to maintain good, the main economic indicators are always in the forefront of the domestic industry. By the end of 2014, Hua Pharmaceutical group total assets of 18 billion yuan, more than 20,000 employees, with more than 40 Zi (sub) company, the main products include penicillin and cephalosporins, such as antibiotics, biotechnology drugs, new formulations, bio-agricultural veterinary drugs, vitamin nutrition health care products 5 large plate more than 700 product regulations. The new project, which is represented by new cephalosporins and new preparations, has been put into production, which marks the opening of the Chinese medicine group to create a modern international first-class pharmaceutical group.
Technology advantages
China Pharmaceutical Group, as one of the first 6 pilot enterprises of technological innovation and the national "863" High-tech Research and Development Program results Industrialization Base, has a staff of more than 4,000 professional and technical personnel, independent research and development capabilities ranked in the forefront of the industry, has taken the lead in the development of the success of Bacillus peptide, the spring mildew element, pingyangmycin, Amphotericin B, Lincomycin, clindamycin, clindamycin phosphate, methyl vancomycin, methyl cobalt amine, EPO and more than 10 kinds of products, and has won the National Invention Award 5, the National Science and Technology Progress Award 19.
Quality Advantage
Hua Pharmaceutical group, depending on the quality of life, since the beginning of the 80 to promote total Quality management (TQM), the establishment of a sound and effective quality management system, the production process in accordance with the various aspects of the GMP standards, in the domestic and foreign markets with high quality reputation. 1986 won the pharmaceutical industry "National Quality Management Award." 2000 through the ISO9001 Quality Management system certification, 2003 through the ISO14001 Environmental Management system certification. At present, has passed the U.S. FDA certification, the EU COS certificate and other international high-end certification products more than 30, 150 main product lines through the new version of GMP certification, access to a new version of GMP Certificate 47, walked in the forefront of the industry.
Development strategy
In the next few years, China Pharmaceutical Group will adhere to the scientific concept of development as the guide, adhering to the "human health first, quality forever first" business purposes, in accordance with the "Integrated integration, advocate innovation, optimize upgrade, do fine and strong" development strategy, do fine and strong traditional advantages of anti-infective drugs plate, do a good job of modern biomedical plate, actively develop professional treatment areas, agricultural veterinary drugs, health and pharmaceutical logistics sector, and strive to pass 3-5 years of efforts to build the enterprise into a "innovative leadership, intensive and efficient, open and win, harmonious and affluent" Xinhua medicine, building into a compact, efficient, sustainable domestic leading modern pharmaceutical group of the world class.